Acceleron Pharma Inc.
(NASDAQ GM: XLRN)
Rigrodsky Law, P.A. is investigating Acceleron Pharma Inc. (“Acceleron”) regarding possible breaches of fiduciary duties and other violations of law related to Acceleron’s agreement to be acquired by Merck & Co. Under the terms of the agreement, Acceleron’s shareholders will receive $180 in cash for each share of Acceleron common stock they own.